--- canonical_name: Phenibut alternate_names: β-phenyl-γ-aminobutyric acid, β-phenyl-GABA, Phenyl-GABA, PhGaba, PGaba, 4-amino-3-phenylbutyric acid, 4-amino-3-phenylbutanoic acid, aminophenylbutyric acid, β-(aminomethyl)benzenepropanoic acid, β-(aminomethyl)hydrocinnamic acid, Phenibut HCl, Fenibut, Phenigam, Phenygam, Phenylgam, Phenigamma, Noofen, Noophen, Anvifen canonical_topic: Phenibut for Health & Longevity short_topic_lc: phenibut creation_date: 2026-1008-1002 creator_ai_fullname: Opus 5.5 ep_keywords: GABA Analogs, GABA-B Receptor Agonists, Gabapentinoids, Nootropics, Anxiolytics --- # Phenibut for Health & Longevity
Evidence Review created on 10/08/2026 using [AI4L](https://github.com/forever-healthy/AI4L) / Opus 5.5 **Also known as:** β-phenyl-γ-aminobutyric acid, β-phenyl-GABA, Phenyl-GABA, PhGaba, PGaba, 4-amino-3-phenylbutyric acid, 4-amino-3-phenylbutanoic acid, aminophenylbutyric acid, β-(aminomethyl)benzenepropanoic acid, β-(aminomethyl)hydrocinnamic acid, Phenibut HCl, Fenibut, Phenigam, Phenygam, Phenylgam, Phenigamma, Noofen, Noophen, Anvifen ## Motivation Phenibut (also sold as Noofen or Anvifen) is a synthetic relative of the brain's main calming chemical messenger, with an added ring structure. It is a prescription medication in Russia and some neighboring countries, while elsewhere it is sold online as a powder or capsule marketed for calm, sleep and mental focus. For health-focused adults, it sits between two interests: steadier mood and better rest, and the long-term costs of relying on a calming drug. The compound was developed in the Soviet Union in the 1960s and has been prescribed there for decades for tension, anxiety and poor sleep. Over the past decade, online shops selling supplements and "brain-boosting" products have carried it to North America, Europe and Australia, where it has drawn the attention of poison centers and regulators. The same substance is therefore treated as a routine prescription drug in one region and as an unapproved product in another. This review examines the human evidence on phenibut's effects on anxiety, sleep and thinking, the nature and severity of its risks, including tolerance and withdrawal, and how both apply to health-focused adults. **[Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol) - [Conclusion](#conclusion)** ## Recommended Reading This section lists in-depth reviews and research articles that discuss phenibut's pharmacology, clinical use, market and risks. - [Phenibut (beta-phenyl-GABA): a tranquilizer and nootropic drug](https://pubmed.ncbi.nlm.nih.gov/11830761/) - Lapin, 2001 Narrative review by a St. Petersburg psychopharmacologist covering phenibut's receptor actions, its mirror-image forms, comparisons with diazepam and piracetam, and its approved clinical uses in Russia. - [Phenibut (4-amino-3-phenyl-butyric acid): Availability, prevalence of use, desired effects and acute toxicity](https://pubmed.ncbi.nlm.nih.gov/26693960/) - Owen et al., 2016 London toxicologists combine a survey of online retailers, drug-forum reports and published cases to describe how phenibut is sold, self-selected doses, sought-after effects and acute toxicity. - [Phenibut (β-Phenyl-γ-Aminobutyric Acid): an Easily Obtainable "Dietary Supplement" With Propensities for Physical Dependence and Addiction](https://pubmed.ncbi.nlm.nih.gov/30852710/) - Jouney, 2019 Psychiatric review of case reports on phenibut dependence, withdrawal and intoxication, with a discussion of treatment options and of why the "dietary supplement" label misrepresents its pharmacology. - [Phenibut: A drug with one too many "buts"](https://pubmed.ncbi.nlm.nih.gov/39197876/) - Gurley & Koturbash, 2024 Dietary-supplement researchers review phenibut's market, intoxication, withdrawal, addiction, interaction potential, how the body absorbs and clears it, and Russian drug fact sheets that are otherwise hard to access. - [Phenibut: Review and Pharmacologic Approaches to Treating Withdrawal](https://pubmed.ncbi.nlm.nih.gov/38339875/) - Penzak & Bulloch, 2024 Clinical pharmacology review of phenibut's actions and regulatory status, with a case-by-case summary of the medications used to manage 29 published withdrawal cases. Note on prioritized experts: no phenibut-specific article, episode or show notes were found from Rhonda Patrick, Andrew Huberman, Chris Kresser, Life Extension Magazine or Lifespan.io. Peter Attia refers to phenibut only briefly: in a short segment of podcast episode #202 on sleep aids and, according to his site's search, in the members-only AMA episode #116; neither public episode page names or discusses it, so neither meets the depth criterion for this list. ## Grokipedia [Phenibut](https://grokipedia.com/page/Phenibut) AI-generated encyclopedia entry covering phenibut's chemistry, pharmacology, dosing, approved uses, dependence, withdrawal, interactions, Soviet-era history, salt versus free-amino-acid forms and legal status worldwide. ## Examine No Examine article on phenibut exists; a direct search of examine.com returned no results. Phenibut is a prescription drug in Russia ([Bonnet et al., 2024 review](https://pubmed.ncbi.nlm.nih.gov/38377332/)), remains in clinical use in some other former Soviet countries ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)) and is not a lawful dietary ingredient in the US, according to the US Food and Drug Administration (FDA) ([FDA: Phenibut in Dietary Supplements](https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements)), which may explain why Examine, which focuses on supplements, does not cover it. ## ConsumerLab [DMHA and Phenibut Are Not Permitted in Dietary Supplements, Warns FDA](https://www.consumerlab.com/recalls/14286/dmha-and-phenibut-are-not-permitted-in-dietary-supplements-warns-fda/) ConsumerLab has no product review of phenibut; this notice reports the FDA's April 2019 warning letters to sellers of supplements containing phenibut or DMHA (a synthetic stimulant). ## Systematic Reviews The systematic reviews below address phenibut's safety, toxicity and withdrawal; none assesses its benefits. - [Safety and Tolerability of the Anxiolytic and Nootropic Drug Phenibut: A Systematic Review of Clinical Trials and Case Reports](https://pubmed.ncbi.nlm.nih.gov/32340063/) - Kupats et al., 2020 Pools 11 clinical trials (583 patients) and 16 intoxication or dependence cases. The authors' institute co-publishes phenibut research with the drug's Latvian manufacturer. - [Clinical Presentations and Treatment of Phenibut Toxicity and Withdrawal: A Systematic Literature Review](https://pubmed.ncbi.nlm.nih.gov/37579098/) - Weleff et al., 2023 Analyzes 62 published toxicity and withdrawal cases: most users bought phenibut online and used other substances; half of toxicity cases required intubation (a breathing tube). - [A systematic review of phenibut withdrawal focusing on complications, therapeutic approaches, and single substance versus polysubstance withdrawal](https://pubmed.ncbi.nlm.nih.gov/38112312/) - Feldman et al., 2023 Reviews 25 withdrawal cases; withdrawal could start within hours, often worsened over the first day, and was similar with or without other substance use. - [A Systematic Review of Phenibut Withdrawals](https://pubmed.ncbi.nlm.nih.gov/39376891/) - Stewart et al., 2024 Summarizes 15 withdrawal case reports from 2010–2023: mostly young men using several grams daily, most with a history of alcohol or drug misuse. No systematic review or meta-analysis has assessed phenibut's claimed benefits (anxiety, sleep or cognition), so the claimed-effect side of the trade-off is unrepresented. ## Mechanism of Action Phenibut is gamma-aminobutyric acid (GABA, the brain's main inhibitory, or calming, chemical messenger) with a phenyl (benzene) ring attached. Its effects are attributed to two targets: - **GABA-B receptors:** Phenibut activates these slow-acting inhibitory receptors, dampening nerve-cell firing. Only the R-enantiomer (one of its two mirror-image forms) binds them, with an affinity constant of 92 µM versus 6 µM for baclofen (a related muscle relaxant; lower values mean tighter binding) ([Dambrova et al., 2008](https://pubmed.ncbi.nlm.nih.gov/18275958/)). - **α2δ calcium-channel subunit:** Both forms also bind the α2δ subunit of voltage-gated calcium channels (a channel part controlling release of excitatory messengers), the target of gabapentinoids (nerve-calming drugs such as gabapentin and pregabalin). R-phenibut binds it four times more tightly than GABA-B receptors ([Zvejniece et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26234470/), co-authored by staff of Noofen maker JSC Olainfarm). Older Russian work proposed weak additional actions at GABA-A receptors (fast-acting inhibitory receptors), on dopamine, and against phenethylamine (a natural stimulant-like brain chemical) ([Lapin, 2001 review](https://pubmed.ncbi.nlm.nih.gov/11830761/)). Which target dominates at human doses is unresolved: Soviet sources frame a GABA-B drug, whereas binding data suggest a gabapentin-like profile. - **Pharmacokinetics:** After a 250 mg oral dose, half-life (time for blood levels to halve) was about 5.3 hours and about 65% was excreted unchanged in urine. Russian fact sheets instead describe up to 95% liver breakdown, an unresolved conflict; neither source names a metabolizing enzyme. Only a small fraction reaches the brain, and no build-up with repeated dosing has been reported ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). ## Historical Context & Evolution Phenibut was developed in the Soviet Union in the 1960s and introduced as a tranquilizer with claimed cognition-enhancing (nootropic) properties ([Lapin, 2001 review](https://pubmed.ncbi.nlm.nih.gov/11830761/)). A later review reports it was developed for the Soviet military to ease anxiety while preserving performance, with much early work never published ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). Russian clinicians used it for tension and anxiety, poor sleep, asthenia (persistent fatigue and weakness), post-traumatic stress, vestibular (balance-organ) disorders and as a calming agent around surgery. Studies continue under the brand names Anvifen and Noofen. Recent ones report less anxiety, fatigue and sleep disturbance, but some are uncontrolled or compare two phenibut regimens ([Esin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36537634/); [Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/), co-authored by staff of JSC Olpha, the Olaine company that produces Noofen). Interest elsewhere came from internet retail rather than new trials: in 2015, 48 online suppliers sold it, and users sought calm and euphoria ([Owen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26693960/)). As use spread, reports of dependence, withdrawal and intoxication accumulated, US poison-center exposures rose sharply after 2015 ([Graves et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32881852/)), and the FDA stated that phenibut is not a lawful dietary ingredient ([FDA: Phenibut in Dietary Supplements](https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements)). A systematic review from a Latvian institute that co-publishes with Noofen's maker found few adverse events at prescribed doses ([Kupats et al., 2020 systematic review](https://pubmed.ncbi.nlm.nih.gov/32340063/)). The two pictures, a well-tolerated anxiolytic (anxiety-reducing drug) and a substance of misuse, rest largely on different doses and populations; no head-to-head study has reconciled them. ## Expected Benefits ### High 🟩 🟩 🟩 No benefit reaches High: no placebo-controlled trial has tested phenibut for anxiety, sleep, fatigue or cognition, and no benefit has been shown in controlled trials from more than one independent research group; other controlled anxiety data come from an active-comparator trial with comparable effects ([Vorob'eva & Rusaya, 2016](https://pubmed.ncbi.nlm.nih.gov/28300804/)) and an add-on trial with a beta-blocker (a blood-pressure drug) ([Knyazkova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/27491166/)). ### Medium 🟩 🟩 #### Reduced Anxiety and Stress-Related Symptoms In a controlled trial in 58 patients with high blood pressure and anxiety-related dizziness, Noofen 500 mg daily reduced anxiety more than betahistine (an anti-vertigo drug) over 60 days ([Duma & Shcherbakova, 2016](https://pubmed.ncbi.nlm.nih.gov/27029450/)). A randomized trial in 62 patients with reduced brain blood flow found anxiety relief comparable to adaptol, another anxiolytic ([Vorob'eva & Rusaya, 2016](https://pubmed.ncbi.nlm.nih.gov/28300804/)). Uncontrolled studies in adjustment disorder (distress after a stressful life event) ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/), co-authored by Noofen-manufacturer staff) and anxiety ([Esin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36537634/)) also reported improvement. None included a placebo group. **Magnitude:** Adjustment Disorder–New Module 20 (ADNM-20, a validated stress-symptom questionnaire) total score fell 14.8 points after 3 weeks of 250 mg three times daily in 90 patients (no control group); the published abstract of the betahistine-controlled trial reports no outcome figure. #### Reduced Dizziness In the same controlled trial of 58 patients with high blood pressure and anxiety-related dizziness, Noofen 500 mg daily reduced dizziness severity more than betahistine over 60 days ([Duma & Shcherbakova, 2016](https://pubmed.ncbi.nlm.nih.gov/27029450/)). Russian clinicians have long used phenibut for vestibular disorders ([Lapin, 2001 review](https://pubmed.ncbi.nlm.nih.gov/11830761/)). No placebo-controlled trial or independent replication exists. **Magnitude:** Dizziness severity fell more with Noofen than with betahistine after 60 days in patients with high blood pressure; the published abstract reports no outcome figure. #### Reduced Fatigue (Asthenia) In the same 58-patient trial, Noofen reduced asthenia more than betahistine ([Duma & Shcherbakova, 2016](https://pubmed.ncbi.nlm.nih.gov/27029450/)). In 53 adults with poor brain blood flow, adding Noofen to standard therapy reduced fatigue in a randomized trial with a standard-therapy-only control group, though the abstract reports no between-group comparison ([Vorob'eva & Rusaya, 2017](https://pubmed.ncbi.nlm.nih.gov/29265084/)). In 60 adolescents with neurasthenia (fatigue with irritability) or residual asthenia, Noofen 500 mg daily was compared with adaptol for 30 days ([Chutko et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25726788/)). None used placebo. **Magnitude:** Responder rates with Noofen were 66.7% (neurasthenia) and 86.7% (residual asthenia), versus 80% and 60% with adaptol (not compared between groups). #### Reduced Headache In the same 58-patient controlled trial, Noofen 500 mg daily reduced headache more than betahistine over 60 days ([Duma & Shcherbakova, 2016](https://pubmed.ncbi.nlm.nih.gov/27029450/)). A randomized trial in 50 women with tension-type headache (the common band-like headache) found adding phenibut 750 mg daily to ibuprofen and tizanidine worthwhile ([Duma, 2015](https://pubmed.ncbi.nlm.nih.gov/26081328/)). In an uncontrolled study of 117 adults, phenibut eased episodic but not chronic tension-type headache ([Esin et al., 2016](https://pubmed.ncbi.nlm.nih.gov/27029449/)). Adding Noophen to metoprolol reduced migraine pain more than metoprolol alone ([Chutko et al., 2017](https://pubmed.ncbi.nlm.nih.gov/28514404/)); none used placebo. **Magnitude:** Headache severity fell more with Noofen than with betahistine after 60 days in patients with high blood pressure; the published abstract reports no outcome figure. #### Greater Heat and Exertion Tolerance ⭕️ Not Central to Health & Longevity In healthy volunteers doing heavy physical work in protective gear, a single 0.25 g dose of phenibut increased heat resistance and preserved working capacity, outperforming bemitil, another Russian performance drug ([Makarov et al., 1997, exertion study](https://pubmed.ncbi.nlm.nih.gov/9162292/)). A placebo-controlled study by the same group found phenibut combined with propranolol (a beta-blocker) the most effective regimen ([Makarov et al., 1997, placebo-controlled study](https://pubmed.ncbi.nlm.nih.gov/9235216/)). This bears on occupational heat and exertion tolerance rather than health or lifespan, and rests on brief abstracts from one research group. **Magnitude:** Heat resistance and working capacity during exertion in heat were better with a single phenibut dose than with the comparison drug; the published abstracts report no outcome figure. ### Low 🟩 #### Improved Subjective Sleep Quality ⚠️ Conflicted Uncontrolled ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/); [Esin et al., 2022, post-COVID study](https://pubmed.ncbi.nlm.nih.gov/36036410/)) and active-comparator ([Vorob'eva & Rusaya, 2016](https://pubmed.ncbi.nlm.nih.gov/28300804/)) studies reported better sleep, without placebo arms. In alcohol withdrawal, sleep recordings changed but subjective sleep did not ([Danilin et al., 1986](https://pubmed.ncbi.nlm.nih.gov/3705831/)). Net reading: no study shows subjective benefit over no treatment. **Magnitude:** In 92 post-COVID patients, a subjective sleep questionnaire score rose from a median of 15 to 25 points after 21 days of 500 mg three times daily (no control group). #### Improved Cognitive Test Performance In post-COVID brain fog, phenibut accompanied better Montreal Cognitive Assessment (MoCA, a thinking and memory screen) and Trail Making Test B (timed attention-switching) scores ([Esin et al., 2022, post-COVID study](https://pubmed.ncbi.nlm.nih.gov/36036410/)). An open randomized trial in children with attention deficit hyperactivity disorder reported better attention and memory ([Zavadenko & Suvorinova, 2014](https://pubmed.ncbi.nlm.nih.gov/25403296/)). **Magnitude:** Median MoCA score rose from 22 to 25 points and Trail Making Test B time fell from 281 to 231 seconds over 21 days (no control group). #### Fewer Tics and Stuttering in Children In 30 children aged 7–13 with tics (sudden involuntary movements or sounds) and stuttering, Noofen reduced tics in 80% and stuttering in 66.7% of cases, without a control group ([Surushkina et al., 2014](https://pubmed.ncbi.nlm.nih.gov/25591517/)). Russian clinicians have long used phenibut for stuttering ([Lapin, 2001 review](https://pubmed.ncbi.nlm.nih.gov/11830761/)). No adult data exist. **Magnitude:** Tics decreased in 80% and stuttering in 66.7% of 30 treated children (no control group). ### Speculative 🟨 #### Neuroprotection After Stroke or Brain Injury R-phenibut reduced brain-tissue loss in rat stroke models and functional deficits after mouse brain injury ([Vavers et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26621244/); [Kupats et al., 2020, brain-injury study](https://pubmed.ncbi.nlm.nih.gov/33274011/)). The basis is animal-only, from the Olainfarm-linked Latvian group. #### Neuropathic Pain Relief Through α2δ binding, R-phenibut reduced nerve-injury pain behaviors in rodents, resembling gabapentin ([Zvejniece et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26234470/)). No human pain data exist; the basis is mechanistic and animal-only. ## Benefit-Modifying Factors - **Genetic polymorphisms:** No gene variants are known to alter phenibut's benefits. Most of a dose was excreted unchanged in urine in a human study, but Russian fact sheets describe mainly liver breakdown ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)), so whether liver-enzyme variants matter is unresolved. - **Baseline biomarker levels:** Studies enrolled people with elevated symptom scores (for example, ADNM-20 of 30 or more ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/))); no data address people with normal anxiety, sleep or cognitive scores, where room for improvement is smaller. - **Sex:** Trials enrolled both sexes (65 of 90 participants in the Latvian study were women) but reported no sex-specific results ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/)). - **Pre-existing conditions:** Reported benefits come from people with adjustment disorder, anxiety, insomnia, post-COVID symptoms, anxiety-related dizziness or tension-type headache; no data address healthy adults seeking performance or longevity gains. - **Age:** One trial enrolled adults aged 60–70 and reported sleep improvement ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/)); in an anxiety trial, both age groups (20–40 and 41–70 years) improved ([Esin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36537634/)). ## Potential Risks & Side Effects ### High 🟥 🟥 🟥 No risk reaches High: phenibut's harms are documented in case reports, case series and poison-center records without comparison groups, not in replicated controlled studies. ### Medium 🟥 🟥 No risk reaches Medium: no controlled trial or comparative observational study has measured phenibut's harms, and the clinical trials that recorded adverse events had no comparison group. ### Low 🟥 #### Tolerance, Dependence and Withdrawal ⚠️ Conflicted Daily multi-gram use produces tolerance and withdrawal with anxiety, insomnia, hallucinations and seizures ([Feldman et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/38112312/)). Trials at 0.25–2 g/day reported adverse events in 5.66%, without assessing dependence ([Kupats et al., 2020 systematic review](https://pubmed.ncbi.nlm.nih.gov/32340063/)). Net reading: dependence is established at high doses and unmeasured at prescribed doses. **Magnitude:** Among 25 published withdrawal cases, 44% required intensive care, 24% required intubation (a breathing tube) and 8% had seizures (no control group). #### Sedation, Respiratory Depression and Coma ⚠️ Conflicted As a central nervous system (CNS) depressant, phenibut can cause coma and breathing failure ([Graves et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32881852/)); a Minnesota series had 19.6% intubated ([McCabe et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30878413/)). A German 17-case series found neither ([Bonnet et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38377332/)). Net reading: severe depression occurs; opioid (strong painkiller) co-use may raise it. **Magnitude:** Of 1,320 US poison-center exposures, 29.0% involved drowsiness, 6.2% coma and 12.6% major effects, with 3 deaths (no control group); in clinical trials, somnolence (sleepiness) affected 1.89% of patients (no control group) ([Kupats et al., 2020 systematic review](https://pubmed.ncbi.nlm.nih.gov/32340063/)). #### Agitation, Delirium and Psychosis Both intoxication and withdrawal can cause agitation, delirium (acute confusion), hallucinations and psychosis (loss of contact with reality), sometimes requiring restraint and antipsychotics (drugs that suppress psychotic symptoms) ([Weleff et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/37579098/); [Hardman et al., 2019](https://pubmed.ncbi.nlm.nih.gov/30501608/)). Frequent co-use of other substances complicates attribution. **Magnitude:** Agitation occurred in 30.4% and confusion in 21.3% of 1,320 US poison-center exposures (no control group) ([Graves et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32881852/)). #### Involuntary Movements Movement disorders (involuntary or abnormal movements) were among the most common symptoms in published phenibut toxicity cases ([Weleff et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/37579098/)), and withdrawal can cause tremor and muscle pain ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). Frequent co-use of other substances complicates attribution. **Magnitude:** Movement disorders ranked among the most common toxicity symptoms in a review of 62 published cases; the review abstract reports no frequency (no control group). #### Rapid Heart Rate and Blood Pressure Changes Toxicity commonly includes tachycardia (fast heart rate), and case reports describe high blood pressure, bradycardia (slow heart rate), dilated pupils and low body temperature ([Graves et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32881852/); [Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). These signs typically resolve with supportive care. **Magnitude:** Tachycardia was reported in 21.9% of 1,320 US poison-center exposures (no control group). #### Liver Fat Accumulation Russian drug fact sheets advise liver monitoring during prolonged use and list fatty liver at 7 g/day or more. One fatal case showed moderate microvesicular steatosis (small fat droplets in liver cells), while two overdose reports found normal liver enzymes ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). **Magnitude:** Russian fact sheets list fatty liver at doses of 7 g/day or more; the literature reports no outcome figure, as only manufacturer warnings and isolated case reports exist (no control group). #### Impaired Coordination and Driving Users describe impaired motor coordination ([Behmer Hansen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37184879/)), and German forensic testing found phenibut, with alcohol, in a driver showing swaying and nystagmus (involuntary eye movements) ([Dziadosz et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38146811/)). Neither source measures how often impairment occurs. **Magnitude:** Not quantified in available studies. The evidence consists of one forensic case and user self-reports, none with a comparison group. #### Gastrointestinal Distress In an analysis of 229 online user reports, gastrointestinal distress (stomach upset) was attributed more often to phenibut than to gabapentin or pregabalin ([Behmer Hansen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37184879/)). The evidence consists of unverified self-reports. **Magnitude:** Gastrointestinal distress was reported more often by phenibut users than by gabapentin or pregabalin users in online reports; the published abstract reports no frequency. ### Speculative 🟨 ## Risk-Modifying Factors - **Genetic polymorphisms:** No gene variants are known to alter phenibut's risks; whether drug-metabolism variants matter is unclear, because a human urine study and Russian fact sheets disagree on how it is eliminated ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **Baseline biomarker levels:** Reduced kidney function (low estimated glomerular filtration rate, eGFR, a measure of kidney filtering) may raise blood levels, as most of a dose leaves unchanged in urine ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)) (theoretical). - **Sex:** Published toxicity and withdrawal cases are 75–100% male ([Graves et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32881852/); [Feldman et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/38112312/)), reflecting who uses high doses; no sex difference in susceptibility has been shown. - **Substance use history:** 73% of reviewed withdrawal cases had prior alcohol or drug misuse and 60% anxiety or depression ([Stewart et al., 2024 systematic review](https://pubmed.ncbi.nlm.nih.gov/39376891/)), marking these groups as most prone to escalation. - **Pregnancy:** A newborn needed lorazepam for withdrawal after maternal use throughout pregnancy ([Pena et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35927183/)); 78 women given 6 days for late gestosis (pregnancy-related high blood pressure) had no reported fetal harm, uncontrolled ([Volkov et al., 1989](https://pubmed.ncbi.nlm.nih.gov/2742068/)). - **Age:** Fifteen-year-olds developed severe poisoning at estimated doses of 1.25–1.75 g ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). Older adults may face greater fall and sedation risk (theoretical). ## Key Interactions & Contraindications - **Alcohol:** Avoid. Additive CNS depression; co-ingestion was common in published toxicity cases, and a driver with phenibut plus alcohol showed marked impairment ([Dziadosz et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38146811/)). No safe timing separation is established. - **Benzodiazepines (sedative anti-anxiety drugs such as alprazolam, diazepam, clonazepam):** Avoid. Additive sedation and respiratory depression; benzodiazepines and alcohol were the most common co-used drugs in published cases ([Weleff et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/37579098/)). Clinicians use them deliberately, under monitoring, to treat phenibut withdrawal. - **Opioids (oxycodone, methadone, tramadol):** Avoid. Additive respiratory depression and coma risk; opioids are among the most frequent co-used substances in published cases ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **Gabapentinoids (gabapentin, pregabalin):** Avoid (theoretical). Shared α2δ target suggests additive sedation, dizziness and dependence; no interaction study exists. - **Baclofen:** Avoid (theoretical) for unsupervised combined use. Shared GABA-B action adds sedation; clinicians have substituted baclofen for phenibut, about 10 mg per gram, to taper dependence ([Samokhvalov et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23391959/)). - **Antiparkinson drugs (levodopa, amantadine, pramipexole):** Monitor. Adding phenibut 250 mg three times daily for 10 days to long-term antiparkinson therapy improved movement, rigidity and tremor in 13 of 16 patients, versus negligible effect of phenibut alone, suggesting potentiation ([Gol'dblat & Lapin, 1986](https://pubmed.ncbi.nlm.nih.gov/3776387/)). - **Beta-blockers (propranolol, bisoprolol, metoprolol):** Monitor. Possible additive calming effect; with propranolol, phenibut gave the greatest heat tolerance in volunteers ([Makarov et al., 1997](https://pubmed.ncbi.nlm.nih.gov/9235216/)), and added to a beta-blocker it reduced anxiety in hypertensive men ([Knyazkova et al., 2015](https://pubmed.ncbi.nlm.nih.gov/27491166/)); no adverse interaction was reported. - **Other sedating prescription drugs (zolpidem, trazodone, mirtazapine, quetiapine):** Caution (theoretical). Additive sedation and impaired coordination; monitoring for excessive drowsiness applies. - **Over-the-counter sedating antihistamines (allergy and sleep-aid drugs such as diphenhydramine, doxylamine):** Caution (theoretical). Additive drowsiness and next-day impairment; separating evening use of both is the usual mitigation. - **Cannabis and THC-containing products (tetrahydrocannabinol, the intoxicating cannabis compound), including THC-contaminated CBD (cannabidiol) products:** Avoid. Cases combining phenibut with cannabinoids required intubation ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **Sedative supplements (kava, valerian, melatonin, passionflower):** Caution (theoretical). Additive sedation; kava also carries its own liver risk, compounding phenibut's liver warning. - **Kratom:** Avoid (theoretical). Phenibut dependence has been reported in people also using kratom ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)); combined sedative and dependence effects are expected. - **Anesthesia and procedural sedation (propofol, midazolam, inhaled anesthetics):** Monitor (theoretical). Additive CNS depression; withdrawal may emerge during a hospital stay if daily use stops abruptly, so disclosing use before procedures is the mitigation. **Populations who should avoid Phenibut:** - Pregnant women, given a documented neonatal withdrawal case ([Pena et al., 2022](https://pubmed.ncbi.nlm.nih.gov/35927183/)) - Breastfeeding women (theoretical; no lactation data exist) - Children and adolescents, given severe poisoning at low gram doses ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)) - People with current or past alcohol or drug use disorder ([Stewart et al., 2024 systematic review](https://pubmed.ncbi.nlm.nih.gov/39376891/)) - People who regularly use alcohol, opioids, benzodiazepines or other sedatives - People with significant kidney impairment (theoretical; no source gives a threshold) ## Risk Mitigation Strategies Doses and timings below follow common practice unless cited. - **Pharmaceutical-grade product:** Using licensed pharmaceutical products rather than online powders mitigates dosing error; tested online products contained 21–1,164 mg per serving ([Cohen et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34550038/)). - **Prescribed dose range:** Keeping to 250–500 mg up to three times daily, under the 2.5 g/day maximum on Russian fact sheets ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)), mitigates toxicity and tolerance. - **Limited course length:** Courses of 3–6 weeks, as in most clinical studies, mitigate dependence; Soviet studies found dose increases of 25–33% were needed after two weeks ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **No redosing for slow onset:** Waiting several hours before any additional dose mitigates overdose; adolescents were severely poisoned after taking more capsules within 3 hours ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **Gradual taper after daily use:** Reducing the dose stepwise over weeks rather than stopping abruptly mitigates withdrawal; outpatient tapers succeeded in reported cases ([Feldman et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/38112312/)), whereas abrupt cessation led to hospital admission in all published cases. - **No sedative combinations:** Avoiding alcohol, opioids, benzodiazepines and other sedatives on dosing days mitigates respiratory depression and coma. - **No driving after dosing:** Not driving or operating machinery until individual effects are known mitigates impaired coordination and crash risk. - **Liver monitoring:** Checking liver enzymes during prolonged use, as Russian fact sheets advise ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)), mitigates undetected liver injury. - **Disclosure to clinicians:** Telling treating clinicians about use mitigates missed diagnosis, because standard drug screens do not detect phenibut ([Penzak & Bulloch, 2024 review](https://pubmed.ncbi.nlm.nih.gov/38339875/)). ## Therapeutic Protocol Doses below are cited to their source; other parameters (timing, cycling, titration steps) reflect common practice. - **Standard clinical dose:** 250 mg three times daily in Latvian general practice ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/)); 500 mg three times daily in Russian anxiety trials ([Esin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36537634/)). - **Daily range and ceiling:** Sources differ: 0.25–2 g/day as the recommended range ([Kupats et al., 2020 systematic review](https://pubmed.ncbi.nlm.nih.gov/32340063/)); 2.5 g/day maximum on Russian fact sheets ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **Self-directed use:** Online users report an average dose of 2.4 g ([Owen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26693960/)), above clinical doses; this approach was popularized by internet nootropic retailers rather than clinicians. - **Clinical approach origin:** The prescription approach was developed in Soviet and Russian psychopharmacology, as summarized from St. Petersburg's Bekhterev Institute ([Lapin, 2001 review](https://pubmed.ncbi.nlm.nih.gov/11830761/)); no Western longevity clinic has published a protocol. - **Course length:** Most studies used 3–6 weeks; anxiety benefits faded within a month after a 21-day course but persisted after a 60-day course ([Esin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36537634/)). - **Time of day:** For sleep, a trial in older adults used 250 mg morning and afternoon, 500 mg at 10 p.m., and 250 mg on night waking ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/)); for anxiety, doses are spread through the day. - **Half-life:** About 5.3 hours ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)), so effects of a single dose wane within the day. - **Single or split dosing:** Split dosing, two to three times daily, is standard in all clinical studies; single large doses are typical of self-directed use. - **Form:** Capsule contents taken as powder gave better sleep-quality and awakening scores than intact capsules ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/)). - **Genetic polymorphisms:** No pharmacogenetic variants (gene differences that alter drug response) are known to guide phenibut dosing, and whether liver enzymes contribute to its clearance is unresolved. - **Sex:** No sex-specific dosing data exist; studies used the same doses for women and men. - **Age:** Adults aged 60–70 were studied at standard doses ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/)); adolescents are especially susceptible to toxicity. - **Baseline biomarker levels:** Reduced kidney function (low eGFR) argues for lower doses because most of a dose was excreted in urine in a human study ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)) (theoretical). - **Pre-existing conditions:** Anxiety, adjustment disorder and insomnia are the studied indications; a substance use history raises the risk of escalation and dependence. ## Discontinuation & Cycling - **Short-term use:** Clinical use is in courses of weeks, not lifelong; no long-term efficacy or safety data exist. - **Withdrawal effects:** After daily use, withdrawal can begin within 2 hours of the last dose and progress over the first day, with anxiety, insomnia, agitation, hallucinations and seizures ([Feldman et al., 2023 systematic review](https://pubmed.ncbi.nlm.nih.gov/38112312/)). - **Fading effect after short courses:** After a 21-day course, anxiety scores no longer differed from baseline 30 days later, whereas the benefit of a 60-day course persisted ([Esin et al., 2022](https://pubmed.ncbi.nlm.nih.gov/36537634/)). - **Tapering:** A dependent patient was switched over 9 weeks to baclofen (about 10 mg per gram of phenibut) and then tapered off ([Samokhvalov et al., 2013](https://pubmed.ncbi.nlm.nih.gov/23391959/)); baclofen alone has failed, with a seizure ([Patt et al., 2023](https://pubmed.ncbi.nlm.nih.gov/36735548/)). - **Cycling:** Tolerance develops within about two weeks of daily use ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)); intermittent rather than daily use is the common practice for limiting tolerance, though no study has tested cycling. ## Sourcing and Quality - **Pharmaceutical products:** Noofen (Latvia), Anvifen and Fenibut (Russia) are manufactured as 250 mg capsules or tablets and dispensed by prescription where approved ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/); [Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/); [Zhezlova et al., 2011](https://pubmed.ncbi.nlm.nih.gov/21809698/)). - **Online products:** Four US supplement brands contained 21–1,164 mg per serving, and amounts rose after FDA warnings ([Cohen et al., 2022](https://pubmed.ncbi.nlm.nih.gov/34550038/)); of six online products, three held less phenibut than labeled, one more ([Upmanis et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39459348/), co-authored by Noofen-maker staff). - **Undeclared ingredients:** Online phenibut capsules contained undeclared ingredients ([Upmanis et al., 2024](https://pubmed.ncbi.nlm.nih.gov/39459348/)), and cognitive-enhancement supplements contained phenibut and other unapproved drugs, some unlisted ([Cohen et al., 2021](https://pubmed.ncbi.nlm.nih.gov/34484905/)). - **Salt form:** Products are sold as the hydrochloride (HCl) salt or as the free amino acid (FAA); the two differ in phenibut content per milligram, so the label's stated form matters. - **What to look for:** Pharmaceutical-brand packaging with batch numbers from a licensed pharmacy, or an independent laboratory certificate of analysis confirming identity and quantity. - **Reputable brands:** No supplement brand can be identified as reputable in the US, where phenibut is not a lawful dietary ingredient ([FDA: Phenibut in Dietary Supplements](https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements)); licensed pharmaceutical brands are the only regulated source. ## Practical Considerations - **Time to effect:** Studies assessed anxiety, sleep and cognitive outcomes after 3 weeks to 2 months; in older adults, capsule contents taken as powder brought faster sleep onset after the 10 p.m. dose than intact capsules ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/)). - **Common pitfalls:** Escalating daily doses as tolerance develops, combining phenibut with alcohol or other sedatives, redosing because effects feel slow, and assuming a "supplement" label means low risk. - **Regulatory status (US):** Phenibut is not a lawful dietary ingredient; the FDA issued warning letters in 2019 and obtained a 2023 injunction against a distributor ([FDA: Phenibut in Dietary Supplements](https://www.fda.gov/food/information-select-dietary-supplement-ingredients-and-other-substances/phenibut-dietary-supplements)). - **Regulatory status (elsewhere):** Phenibut is a prescription drug in Russia ([Bonnet et al., 2024 review](https://pubmed.ncbi.nlm.nih.gov/38377332/)) and Latvia ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/)); Australia, France, Italy and Lithuania prohibit it ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)). - **Drug testing:** Standard urine drug screens do not detect phenibut, which can delay diagnosis of toxicity or withdrawal ([Penzak & Bulloch, 2024 review](https://pubmed.ncbi.nlm.nih.gov/38339875/)). - **Cost and access:** Inexpensive online, at US$0.23–1.60 per gram in 2015 ([Owen et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26693960/)), but regulated pharmaceutical products are accessible only where it is prescribed. ## Interaction with Foundational Habits - **Sleep:** Potentiating in the short term: trials report better subjective sleep. Blunting with daily use: tolerance develops and withdrawal causes insomnia. Studied sleep regimens placed the largest dose at 10 p.m. ([Esin et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38465815/)); combining phenibut with alcohol as a sleep aid compounds sedation. - **Nutrition:** No known nutrient interactions or depletions. Indirect: users report gastrointestinal distress more often with phenibut than with gabapentin or pregabalin ([Behmer Hansen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37184879/)); avoiding alcohol on dosing days is the main dietary consideration. - **Exercise:** No studies on training or performance. Indirect blunting is plausible through sedation and impaired motor coordination ([Behmer Hansen et al., 2023](https://pubmed.ncbi.nlm.nih.gov/37184879/)), so technical or balance-dependent sessions after dosing carry added injury risk (theoretical). - **Stress management:** Direct, calming effect via GABA-B and α2δ actions, with reduced anxiety scores in uncontrolled studies. Anxiety returns after short courses and rises during withdrawal, so reliance on phenibut can displace behavioral stress skills such as breathing practice or therapy. ## Monitoring Protocol & Defining Success Baseline testing before starting covers liver enzymes and kidney function, as safety checks given the liver warnings on Russian fact sheets and urinary excretion of most of a dose in a human study ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)), plus validated anxiety and sleep questionnaires to anchor any later change. A baseline resting heart rate gives a reference for detecting toxicity. Ongoing monitoring repeats the questionnaires at 2 and 4 weeks, then at the end of each course; liver enzymes, kidney function and heart rate are rechecked every 4–6 weeks during continuous use. A dose increase needed to keep the same effect, or symptoms between doses, signals tolerance, which preceded escalation and withdrawal in published dependence cases. Success means a meaningful drop from baseline questionnaire scores at a stable, prescribed-range dose without escalation, daytime sedation or rebound symptoms between doses. | Biomarker | Optimal Functional Range | Why Measure It? | Context/Notes | |-----------|--------------------------|-----------------|---------------| | ALT and AST | ALT about 7–56 U/L; AST about 10–40 U/L (standard reference range) | Safety check: liver warning on fact sheets | ALT and AST (alanine and aspartate aminotransferase) are liver-cell enzymes; ranges vary by laboratory; no fasting needed; Russian fact sheets advise liver monitoring during prolonged use ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)) | | Creatinine with eGFR | Creatinine about 0.6–1.3 mg/dL (standard reference range); eGFR: no established target, track change from own baseline | Safety check: renal elimination | eGFR (estimated glomerular filtration rate) estimates kidney filtering from blood creatinine; ranges vary by laboratory and sex; about 65% of a dose leaves unchanged in urine ([Gurley & Koturbash, 2024 review](https://pubmed.ncbi.nlm.nih.gov/39197876/)); heavy exercise in the 24 hours before testing can raise creatinine | | Resting heart rate | 60–100 beats per minute (standard reference range) | Safety check: tachycardia signals toxicity | Measured seated after 5 minutes of rest, same time of day; tachycardia was reported in 21.9% of poison-center exposures ([Graves et al., 2020](https://pubmed.ncbi.nlm.nih.gov/32881852/)) | | GAD-7 score | No established target; track change from own baseline | Expected to change: anxiety | GAD-7 (Generalized Anxiety Disorder 7-item scale) is a validated self-rated questionnaire; most informative when completed at the same time of day, ideally before the morning dose | | Insomnia Severity Index | No established target; track change from own baseline | Expected to change: sleep | The Insomnia Severity Index is a validated 7-item self-rated questionnaire covering the previous two weeks; commonly paired with a sleep diary | Qualitative markers: - Subjective sleep quality and ease of falling asleep - Daytime alertness and absence of grogginess - Anxiety level between doses, as an early sign of rebound - Need to raise the dose for the same effect - Mood, irritability and motor coordination - Mental clarity and concentration ## Emerging Research - **No registered trials:** A ClinicalTrials.gov search on 2026-10-06 for phenibut, fenibut, Noofen and Anvifen found no registered studies, ongoing or completed; there are therefore no trial results to anticipate. - **Placebo-controlled efficacy trials:** The 2025 Noofen study used a validated questionnaire in general practice ([Tērauds et al., 2025](https://pubmed.ncbi.nlm.nih.gov/40807194/)); a randomized placebo-controlled follow-up would either confirm an anxiety benefit (strengthening the case) or show placebo-level effects (weakening it). - **Dependence at prescribed doses:** No study has measured dependence or withdrawal after courses at 0.25–2 g/day ([Kupats et al., 2020 systematic review](https://pubmed.ncbi.nlm.nih.gov/32340063/)); finding none would narrow the risk to high-dose use, while finding it would weaken the case. - **R-phenibut development:** The Latvian group is studying the R-enantiomer for stroke, brain injury and nerve pain in animals ([Vavers et al., 2016](https://pubmed.ncbi.nlm.nih.gov/26621244/); [Zvejniece et al., 2015](https://pubmed.ncbi.nlm.nih.gov/26234470/)); human trials would test whether these effects translate. - **Withdrawal treatment:** No comparative study of withdrawal treatments exists ([Penzak & Bulloch, 2024 review](https://pubmed.ncbi.nlm.nih.gov/38339875/)), and reliance on baclofen alone has been questioned ([Feldman, 2024](https://pubmed.ncbi.nlm.nih.gov/38752524/)); standardized protocols would reduce the severity of discontinuation. - **Surveillance of use and analogues:** Wastewater testing in Australia detected phenibut and its analogue 4-fluorophenibut ([Jaunay et al., 2024](https://pubmed.ncbi.nlm.nih.gov/38286292/)), indicating continuing use despite prohibition. ## Conclusion Phenibut is a synthetic relative of the brain's main calming messenger, prescribed for decades in Russia and nearby countries for anxiety and poor sleep, and sold elsewhere online for calm and focus. The case for benefit rests on clinical studies from Russia and Latvia reporting less anxiety, better sleep, less fatigue and better thinking-test scores. None compared phenibut with a placebo, only a few compared it with another drug, several were small, and some were written by staff of the company that makes the leading brand or by a research institute that publishes with it. These benefits are therefore unconfirmed rather than disproven. The risk record comes from a different source: reports of individual patients, hospital records and poison-center records, mostly involving daily use of far larger amounts than prescribed, often alongside alcohol or other drugs. Within those records, a need for ever-larger amounts, dependence and a withdrawal state that can include hallucinations, seizures and intensive care recur, as do deep sleepiness, unresponsiveness and agitation after overdose. The prescribed-use studies recorded few side effects but did not look for dependence in a systematic way, so the safety of short courses at prescribed amounts remains uncertain. Product quality adds further uncertainty, because online products often contain more or less than labeled. Nothing links phenibut to slower aging or longer life. For health-focused adults, the evidence describes a short-term calming drug with an unproven benefit profile and a well-documented capacity for dependence and withdrawal that grows with the amount used. **[Top](#top) - [Benefits](#expected-benefits) - [Risks](#potential-risks--side-effects) - [Protocol](#therapeutic-protocol)**